Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 Our Vision &Purpose Genetic Signatures improves patient care and outcomes by developing innovative diagnostic technologies which simplify molecular pathology. The Genetic Signatures' proprietary 3base TM platform technology forms the cornerstone of our EasyScreen ™ pathogen detection kits, and reduces the genetic complexity of infection detection in molecular testing. Our tests enable hospital and pathology facilities to use standard equipment and procedures to screen more accurately for a wide range of infectious diseases (pathogens). Results are delivered in hours, compared with days for traditional methods. Timely and accurate diagnosis results in appropriate infection control measures that reduce costs and save lives. By minimising customers' workloads and maximising results, Genetic Signatures delivers value to both customers and shareholders while improving community health globally. Chairman’s Letter........................... 4 CEO Report. .................................... 6 Full Year Results Highlights. ......... 8 Commercialisation Update. ........ 10 EasyScreen TM Kits........................ 14 Our People. ................................... 16 SARS-CoV-2 Update..................... 18 Financial Report 2021. ................ 20 Analysis of Shareholdings........... 70 Contents